Comment
Author: Admin | 2025-04-28
Torsemide has been studied in controlled trials in patients with New York Heart Association Class II to Class IV heart failure. Patients who received 10 mg to 20 mg of daily torsemide in these studies achieved significantly greater reductions in weight and edema than did patients who received placebo. When torsemide is first administered, daily urinary sodium excretion increases for at least a week. With chronic administration, however, daily sodium loss comes into balance with dietary sodium intake. If the administration of torsemide is suddenly stopped, blood pressure returns to pretreatment levels over several days, without overshoot. Torsemide has been administered together with β-adrenergic blocking agents, ACE inhibitors, and calcium-channel blockers. Adverse drug interactions have not been observed, and special dosage adjustment has not been necessary. 12.3 Pharmacokinetics Absorption Torsemide reaches peak plasma concentration (Cmax) within 2.5 hours after oral administration of SOAANZ. Cmax and area under the serum concentration-time curve (AUC) of torsemide after oral administration are proportional to dose over the range of 2.5 mg to 200 mg. Effect of Food Administration of SOAANZ with a high fat, high calorie meal in healthy adults delays the time to Cmax by about 45 minutes, increases Cmax by 100% and increases area under the plasma concentration over time curve (AUC) by 48%. No clinically significant change in overall diuretic activity was observed. Distribution The volume of distribution of torsemide is 12 to 15 liters in normal adults or in patients with mild to moderate renal failure or congestive heart failure.
Add Comment